Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsGilead Lancaster, MD
Associate Clinical ProfessorAbout
Research
Publications
2025
Incidence and Predictors of Candida Endocarditis in Hospitalized Patients With Candidemia: Insights From the National Inpatient Sample (2016 to 2022)
Meyahnwi D, Siraw B, Tafesse Y, Issaka Y, Zinyandu T, Ahmed A, Opoku I, Lancaster G. Incidence and Predictors of Candida Endocarditis in Hospitalized Patients With Candidemia: Insights From the National Inpatient Sample (2016 to 2022). The American Journal Of Cardiology 2025, 254: 63-68. PMID: 40581131, DOI: 10.1016/j.amjcard.2025.06.023.Peer-Reviewed Original ResearchCandida endocarditisIV drug usePredictors of CEPrevalence of non-albicans Candida speciesProsthetic valvesNon-albicans Candida speciesHospitalized patientsHistory of IV drug useComplication of candidemiaProlonged antifungal therapyMultivariate logistic regression analysisAssociated with longer hospitalSolid organ malignanciesLife-threatening complicationsRetrospective cohort studyDrug useIn-Hospital MortalityHigher hospital costsLogistic regression analysisMultivariate regression analysisNational Inpatient SampleRegression analysisAntifungal therapyOrgan malignanciesFactors associated with lower oddsMTEER in Africa: a lost opportunity
Ahmed A, Kaddoura R, Ahmed M, Lancaster G. MTEER in Africa: a lost opportunity. Journal Of Cardiology & Current Research 2025, 18: 23-23. DOI: 10.15406/jccr.2025.18.00619.Peer-Reviewed Original ResearchHeartfelt Progress: The Triumphs Of Non-invasive Remote Patient Monitoring In Mitigating Heart Failure Readmissions
REHAN M, ABDULLAH A, LANCASTER G. Heartfelt Progress: The Triumphs Of Non-invasive Remote Patient Monitoring In Mitigating Heart Failure Readmissions. Journal Of Cardiac Failure 2025, 31: 303. DOI: 10.1016/j.cardfail.2024.10.310.Peer-Reviewed Original ResearchCongestive heart failureCongestive heart failure patientsRemote patient monitoring programReadmission ratesOutpatient monitoringHospital data of patientsImplantable pulmonary artery pressure monitorPulmonary artery pressure monitoringComparison to patientsData of patientsArterial pressure monitoringHeart failure readmissionDecreased 30-day readmissionsHeart failureBaseline parametersCompare outcomesBlood pressureCardioMEMSPatientsPressure monitoringWeeks post-dischargePatient monitoringMedical costsReadmissionVital signs
2024
Management of Cardiogenic Shock in Mitral Valve Diseases: A Review Article
Ahmed A, Badheeb M, Boyea K, Kaddoura R, Webber F, Lane T, Lancaster G. Management of Cardiogenic Shock in Mitral Valve Diseases: A Review Article. Journal Of Heart Valve Disease Innovation 2024, 29: 60-70. DOI: 10.36923/jhvd.v29i1.239.Peer-Reviewed Original ResearchMitral valve diseaseAcute coronary syndromeCardiogenic shockSurgical interventionValve diseaseValvular heart diseaseCatheter-based interventionsManagement of cardiogenic shockCases of CSMechanical circulatory supportSurgical riskCardiac tamponadeClinical presentationMechanical complicationsFavorable outcomeCoronary syndromeHeart diseaseManagement dilemmaCirculatory supportGold standardMortality rateField of cardiologyPatientsDiseaseReview articleOutcomes of Mitral Valve Transcatheter Edge-To-Edge Repair In Patients With Chronic Kidney Disease: A Systematic Review And Meta-Analysis
Ahmed A, Webber F, Kaddoura R, Badheeb M, Marnet E, Nayak S, Mashiul M, Aggarwal A, Lancaster G. Outcomes of Mitral Valve Transcatheter Edge-To-Edge Repair In Patients With Chronic Kidney Disease: A Systematic Review And Meta-Analysis. Journal Of Heart Valve Disease Innovation 2024, 29: 45-50. DOI: 10.36923/jhvd.v29i1.214.Peer-Reviewed Original ResearchChronic kidney diseaseTranscatheter edge-to-edge repairEdge-to-edge repairLong-term mortalityGroup 1Kidney diseaseM-TEEROpen surgeryKidney functionMitral valve transcatheter edge-to-edge repairGroup 2Odds ratioGroup 3Surgical mitral valve repairMild chronic kidney diseaseMild kidney impairmentMitral valve repairMitral valve regurgitationMeta-analysisNormal kidney functionEnd-stage kidney diseaseCohort observational studyImpaired kidney functionModerate-to-severeConfidence intervalsCrossroads of Care: Navigating Injection Drug Use-Associated Endocarditis
Stolear A, Dulgher M, Kaminsky L, Ramponi F, Lancaster G. Crossroads of Care: Navigating Injection Drug Use-Associated Endocarditis. Cureus 2024, 16: e62490. PMID: 39015851, PMCID: PMC11251736, DOI: 10.7759/cureus.62490.Peer-Reviewed Original ResearchMethicillin-susceptible Staphylococcus aureusInjection drug useAddiction medicine specialistsInfective endocarditisComplications of injection drug useActive injection drug useSubstance use disordersMedicine specialistsTricuspid valve repairPulmonary septic emboliTricuspid valve surgeryTricuspid valve vegetationManagement of IEIndividualized surgical interventionDrug useRecurrent IEAntibiotic coursesValve surgerySeptic emboliValve repairValve vegetationsAntibiotic therapySix-week follow-upSurgical interventionIllicit drug useIn-Hospital Outcomes and 30-Day Readmission Rate After Transcatheter and Surgical Aortic Valve Replacement in Liver Cirrhosis: A Contemporary Propensity-Matched Analysis
Aggarwal A, Jang S, Vardhan S, Webber F, Alam M, Vardhan M, Lancaster G, Ahmad Y, Vora A, Zarich S, Inglessis-Azuaje I, Elmariah S, Forrest J, Davila C. In-Hospital Outcomes and 30-Day Readmission Rate After Transcatheter and Surgical Aortic Valve Replacement in Liver Cirrhosis: A Contemporary Propensity-Matched Analysis. Structural Heart 2024, 8: 100327. PMID: 39670045, PMCID: PMC11632700, DOI: 10.1016/j.shj.2024.100327.Peer-Reviewed Original ResearchSurgical aortic valve replacementTranscatheter aortic valve replacementAortic valve replacementTranscatheter aortic valve replacement groupValve replacementIn-Hospital MortalityHepatorenal syndromeReadmission ratesCardiogenic shockLiver cirrhosisVascular complicationsIn-HospitalOutcomes of transcatheter aortic valve replacementSurgical risk prediction modelsSurgical aortic valve replacement groupAssociated with significantly lower ratesRates of in-hospital mortalityLimited contemporary dataIn-Hospital OutcomesSignificantly lower ratesNationwide Readmissions DatabaseCardiac surgeryPeriprocedural morbidityTherapeutic optionsClinical characteristics
2023
TCT-67 Comparison of In-Hospital Outcomes and 30-Day Readmission Rates Between Patients Who Underwent TAVR Versus SAVR for Aortic Stenosis in Liver Cirrhosis: A Propensity-Matched Analysis
Aggarwal A, Jang S, Vardhan S, Webber F, Lancaster G, Zarich S, Vora A, Elmariah S, Davila C. TCT-67 Comparison of In-Hospital Outcomes and 30-Day Readmission Rates Between Patients Who Underwent TAVR Versus SAVR for Aortic Stenosis in Liver Cirrhosis: A Propensity-Matched Analysis. Journal Of The American College Of Cardiology 2023, 82: b27. DOI: 10.1016/j.jacc.2023.09.072.Peer-Reviewed Original ResearchCOMPARISON OF IN - HOSPITAL OUTCOMES AND THIRTY - DAY READMISSION RATES BETWEEN PATIENTS WHO UNDERWENT TAVR VERSUS SAVR FOR AORTIC STENOSIS IN LIVER CIRRHOSIS: RESULTS FROM NATIONWIDE READMISSIONS DATABASE
Aggarwal A, Jang S, Webber F, Shkolnik E, Pinto E, Lancaster G, Zarich S. COMPARISON OF IN - HOSPITAL OUTCOMES AND THIRTY - DAY READMISSION RATES BETWEEN PATIENTS WHO UNDERWENT TAVR VERSUS SAVR FOR AORTIC STENOSIS IN LIVER CIRRHOSIS: RESULTS FROM NATIONWIDE READMISSIONS DATABASE. Journal Of The American College Of Cardiology 2023, 81: 1020. DOI: 10.1016/s0735-1097(23)01464-x.Peer-Reviewed Original ResearchColchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial
Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J, Kashyap N, Paredes C, Patel P, Lu J, Kandel P, Song C, Khan M, Huang H, Haq F, Ahmad R, Howes C, Cambi B, Lancaster G, Cleman M, Dela Cruz C, Parise H, Lansky A. Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open 2023, 13: e067910. PMID: 36828654, PMCID: PMC9971831, DOI: 10.1136/bmjopen-2022-067910.Peer-Reviewed Original ResearchConceptsStandard of careHigh-intensity rosuvastatinElectronic medical recordsCOVID-19 diseaseMedical recordsPrimary endpointThromboembolic eventsYale New Haven Health SystemSevere COVID-19 diseaseCOVID-19Prespecified primary endpointVenous thromboembolic eventsRisk of progressionCombination of colchicineSafety monitoring boardCare armHispanics/LatinosTherapeutic anticoagulationIndex hospitalisationIll patientsMedian ageFuture trialsEffect of colchicineClinical trialsMonitoring board